This information together suggests that inhibition of the Arf1-mediated lipid metabolic pathway in tumor cells has the effect of “one stone killing two birds”, that is, it not only kills CSCs but also alternates TME and activates systemic anti-tumor immunity. Here, ARF1 is linked to neoplasm.